Supplements

Table S1 Characteristics of ACS inpatients who underwent PCI

Characteristics and medication	Postpolicy (n=8982)	Prepolicy (n=22778)	Student's t/χ^2	p value
Diagnostic classification				
Unstable angina pectoris	3933(43.79%)	9691(42.55%)		
Non-ST-segment elevation MI	2054(22.87%)	5351(23.49%)	4.61	0.2026
ST-segment elevation MI	2966(33.02%)	7649(33.58%)		
Undetermined	29(0.32%)	87(0.38%)		
Age, years[†]	65.03 (11.61)	65.52 (11.52)	4.28	<.0001
Age group, years				
<50	925 (10.30%)	2097 (9.21%)		
50-59	1587 (17.67%)	4082 (17.92%)		
60-69	3209 (35.73%)	8323 (36.54%)	28.56	<.0001
70-79	2343 (26.09%)	5600 (24.59%)		
≥80	918 (10.21%)	2676 (11.74%)		
Sex				
Male	6786 (75.55%)	17223 (75.60%)	0.01	0.9038
Female	2196 (24.45%)	5555 (24.39%)		
Medical insurance				
Yes	7935 (88.34%)	20310 (89.16%)		
No	1047 (11.66%)	2468 (10.84%)	4.42	0.0356
Medical history				
Diabetes	2783 (30.98%)	7511 (32.97%)	11.65	0.0006
Hypertension	5271 (58.68%)	14451 (63.44%)	61.98	<.0001
Hyperlipidaemia	2742 (30.53%)	76.38 (33.53%)	26.43	<.0001
Stroke	81 (0.90%)	265 (1.16%)	4.09	0.0431
Chronic kidney disease	844 (9.40%)	2391 (10.50%)	8.53	0.0035
Chronic obstructive pulmonary disease	251 (2.79%)	764 (3.35%)	6.52	0.0107
Previous MI	646 (7.19%)	2028 (8.90%)	24.46	<.0001
Previous CABG	264 (2.94%)	1002 (4.40%)	35.87	<.0001
Hospital level				
Tertiary hospital	7984 (88.89%)	20788 (91.26%)	42.62	<.0001
Secondary hospital	998 (11.11%)	1990 (8.74%)		
NYHA or Killip functional classification[‡]				
I	2492 (60.59%)	4350 (55.68%)		
II or III	1499 (36.45%)	3283 (42.03%)	37.08	<.0001
IV	122 (2.96%)	179 (2.29%)		
Number of coronary stents implanted[‡]				
1	4244 (73.96%)	7897 (74.36%)		
2	1134 (19.76%)	2257 (21.25%)	35.57	<.0001
3	290 (5.05%)	402 (3.79%)		
4 or more	70 (1.22%)	66 (0.60%)		

Characteristics and medication	Postpolicy (n=8982)	Prepolicy (n=22778)	Student's t/χ^2	p value
At least one bid-winning stent‡				
Yes	6086 (86.52%)	8950 (55.67%)	2049.02	<.0001
No	948 (13.48%)	7127 (44.33%)		
Medication prescribed at outpatient visits during the year after PCI				
Aspirin	6255 (69.64%)	15739 (69.10)	0.89	0.3459
Clopidogrel	4691 (52.23%)	12246 (53.76)	6.10	0.0135
Metoprolol	4777 (53.18%)	13051 (57.30)	44.24	<.0001
Ticagrelor	4037 (44.95%)	11365 (49.89)	63.17	<.0001
Atorvastatin	5392 (60.03%)	14113 (61.96)	10.10	0.0015
Ezetimibe	1556 (17.32%)	2799 (12.29)	138.04	<.0001
Sacubitril/valsartan	2342 (26.07%)	2210 (9.70)	1406.29	<.0001
Trimetazidine dihydrochloride	443 (4.93%)	1918 (8.42)	113.91	<.0001
Pravastatin sodium	750 (8.35%)	2387 (10.48)	32.81	<.0001
Nicorandil	502 (5.59%)	694 (3.05)	114.86	<.0001
Isosorbide dinitrate	1409 (15.69%)	4260 (18.70)	39.94	<.0001
Rosuvastatin	2296 (25.56%)	4495 (19.73)	130.17	<.0001
Others	541(6.02%)	1175 (5.16)	9.42	0.0021

† Age is presented as the mean (SD) and was compared between post- and prepolicy cohorts by Student's t test; all other variables and age groups are presented as n (%) and were compared between the post- and prepolicy cohorts by the χ^2 test.

‡ There were missing data for these variables.

Table S2 Characteristics of the two PS-matched cohorts

Characteristics	Postpolicy (n=4098)	Prepolicy (n=4098)	Student's t/χ^2	p value
Age, years†	64.49 (12.01)	64.48 (12.02)	-0.05	0.9597
Age group, years				
<60	1261 (30.77%)	1260 (30.75%)	0.05	0.9746
60-69	1424 (34.75%)	1433 (34.97%)		
≥70	1413 (34.48%)	1405 (34.29%)		
Sex				
Male	3173 (77.43%)	3173(77.43%)	0.00	1.0000
Female	925 (22.57%)	925 (22.57%)		
Medical insurance				
Yes	3588 (87.55%)	3591 (87.63%)	0.01	0.9199
No	510 (12.45%)	507 (12.37%)		
Previous medical history				
Diabetes	1216 (29.67%)	1216 (29.67%)	0.00	1.0000
Hypertension	2329 (56.83%)	2329 (56.83%)	0.00	1.0000
CABG	86 (2.10%)	86 (2.10%)	0.00	1.0000
Hospital level				
Tertiary hospital	3588 (87.55%)	3588 (87.55%)	0.00	1.0000
Secondary hospital	1225 (7.29%)	1461 (6.41%)		
Severity of heart function				
NYHA or Killip functional classification at IV	108 (2.64%)	108 (2.64%)	0.00	1.0000
NYHA or Killip functional classification not at IV	3990 (97.36%)	3990 (97.36%)		

† Age is presented as the mean (SD) and was compared between the post- and prepolicy cohorts by Student's t test; all other variables and age groups are presented as n (%) and were compared between the post- and prepolicy cohorts by the χ^2 test.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Figure S1 Data screening process used in the study

A. Based on real-world data †

B. Based on PS-matched data †

† TMC: total medical costs

Figure S2 Tornado diagram: ICER (postpolicy vs. prepolicy)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

A. Based on real-world data

B. Based on PS-matched data

Fig. S3 ICE scatterplot (postpolicy vs. prepolicy)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

A. Based on real-world data

B. Based on PS-matched data

Figure S4 Cost-effectiveness scatterplot (postpolicy vs. prepolicy)